 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 October 2002 | Volume 137 Issue 8 | Pages 678-687
Purpose: Breast cancer in men is uncommon; 1500 new cases are diagnosed in the United States yearly. Optimal management of breast cancer in men is unknown because the rarity of the disease precludes large randomized trials. A review of the literature was undertaken with emphasis on articles published over a 10-year period.
Data Sources: Articles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies.
Study Selection: All retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men.
Data Extraction: Data on the epidemiology, risk factors, genetics, pathology, molecular markers, prognostic factors, therapy, and outcomes of breast cancer in men.
Data Synthesis: Carcinoma of the male breast accounts for 0.8% of all breast cancers. Risk factors include testicular disease, benign breast conditions, age, Jewish ancestry, family history, and the Klinefelter syndrome. BRCA2 mutations predispose men to breast cancer and may account for 4% to 14% of all cases. Pathology data were reviewed: 81% of tumors were estrogen receptor positive, 74% were progesterone receptor positive, 37% overexpressed c-erbB-2, 30% overexpressed p53, 79% overexpressed Bcl-2, 51% overexpressed cyclin D1, and 39% overexpressed epidermal growth factor receptor. Prognostic factors include tumor size, histologic grade, and lymph node status; survival is similar to that of breast cancer in women when patients are matched for age and stage. Adjuvant hormonal therapy and chemotherapy, using the same guidelines as for women, are recommended for men. Hormonal therapy is the primary therapy for metastatic disease; chemotherapy should be reserved for hormone-refractory disease.
Conclusion: Breast cancer is similar in men and women; however, breast cancer in men is more frequently hormone receptor positive and may be more sensitive to hormonal therapy.
Author and Article Information
From the University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Grant Support: In part by the Nellie B. Connally Breast Cancer Research Fund.
Requests for Single Reprints: Sharon H. Giordano, MD, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030; e-mail, sgiordano{at}mdanderson.org.
Current Author Addresses: Drs. Giordano, Buzdar, and Hortobagyi: The University of Texas M.D. Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030. REVIEW
Breast Cancer in Men
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  L. M. Arendt and L. A. Schuler Prolactin Drives Estrogen Receptor-{alpha}-Dependent Ductal Expansion and Synergizes with Transforming Growth Factor-{alpha} to Induce Mammary Tumors in Males Am. J. Pathol., January 1, 2008; 172(1): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Braunstein Gynecomastia N. Engl. J. Med., September 20, 2007; 357(12): 1229 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 N. V. Dimitrov, P. Colucci, and S. Nagpal Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer Oncologist, July 1, 2007; 12(7): 798 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Crew, A. I. Neugut, X. Wang, J. S. Jacobson, V. R. Grann, G. Raptis, and D. L. Hershman Racial Disparities in Treatment and Survival of Male Breast Cancer J. Clin. Oncol., March 20, 2007; 25(9): 1089 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ioka, H. Tsukuma, W. Ajiki, and A. Oshima Survival of Male Breast Cancer Patients: A Population-Based Study in Osaka, Japan Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 699 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bojesen, S. Juul, N. H. Birkebaek, and C. H. Gravholt Morbidity in Klinefelter Syndrome: A Danish Register Study Based on Hospital Discharge Diagnoses J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1254 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Giordano A Review of the Diagnosis and Management of Male Breast Cancer Oncologist, August 1, 2005; 10(7): 471 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Sirchia, L. Ramoscelli, F. R. Grati, F. Barbera, D. Coradini, F. Rossella, G. Porta, E. Lesma, A. Ruggeri, P. Radice, et al. Loss of the Inactive X Chromosome and Replication of the Active X in BRCA1-Defective and Wild-type Breast Cancer Cells Cancer Res., March 15, 2005; 65(6): 2139 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Weiss, K. B. Moysich, and H. Swede Epidemiology of Male Breast Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Duong, J. GH. Dinoulos, A. Gupta, T. Bryk, M. Saps, C. Di Lorenzo, A. Sveen, M. Waseem, and L. L. Kin Index of Suspicion Pediatr. Rev., January 1, 2005; 26(1): 23 - 33. [Full Text] [PDF]
|
|
|
|
|
|
C. E. Ford, M. Faedo, R. Crouch, J. S. Lawson, and W. D. Rawlinson Progression from Normal Breast Pathology to Breast Cancer Is Associated with Increasing Prevalence of Mouse Mammary Tumor Virus-Like Sequences in Men and Women Cancer Res., July 15, 2004; 64(14): 4755 - 4759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Lee and R. J. Ellis Male Breast Cancer During Finasteride Therapy J Natl Cancer Inst, February 18, 2004; 96(4): 338 - 339. [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Jackson Breast Cancer in Men Ann Intern Med, August 19, 2003; 139(4): 305 - 305. [Full Text] [PDF]
|
|
|
|
 |
|
 G. H Perkins and L. P Middleton Breast cancer in men BMJ, July 31, 2003; 327(7409): 239 - 240. [Full Text] [PDF]
|
|
Article
